Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2014

View Archived Issues

Results from phase I trial of PF-06438179, a biosimilar to infliximab

ABP-501 proves equivalent to adalimumab in healthy volunteers

NNC-0151-0000 development halted, second-generation compound shows improved profile

Selexipag meets endpoint in pivotal phase III study in PAH

Inovio Pharmaceuticals expands license agreement with the University of Pennsylvania

Phase III perampanel trial meets primary endpoint in primary generalized tonic-clonic seizures

Isis Pharmaceuticals earns milestone payment under Biogen Idec collaboration

PsiOxus initiates phase I/II study of enadenotucirev for ovarian cancer

GW Pharmaceuticals reports expanded-access data for Epidiolex

Eculizumab receives U.S. orphan drug designation for myasthenia gravis

FDA award orphan drug designation to COTI-2 for ovarian cancer

Senhwa Biosciences begins phase I/II trial of CX-4945

Galapagos provides progress update on R&D programs

Bioequivalence of LY-2963016 to originator insulin glargine

GlaxoSmithKline presents new IFN-alpha inducers

GlaxoSmithKline describe novel DGAT1 inhibitors

Novel phosphodiesterase PDE10A inhibitors synthesized at Merck & Co.

Piramal Enterprises patents new proinflammatory cytokine inhibitors

Enrollment complete in phase IIa trial of GALE-301 immunotherapy in gynecological cancer

New IDO inhibitors prepared by Vertex Pharmaceuticals

Immunomodulator HMPL-523 enters first-in-human trial

Selecta Biosciences outlines pipeline progress and reveals new product candidate

Endocyte regains rights to vintafolide

Allergan acknowledges second unsolicited exchange offer from Valeant

BMS-817399 fails to improve rheumatoid arthritis in phase II proof-of-concept study

Takeda terminates development of orteronel for prostate cancer

Boehringer Ingelheim and Lilly resubmit empagliflozin NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...